

COVID-19 Monoclonal Antibodies & Administration Codes									
Revised: July 1, 2022									
Submit claim for administration fee with the appropriate Monoclonal Antibody HCPCS (See NOTE tab for additional instructions)									
#	HCPCS	CPT/HCPCS Name, Description, Dose	Labeler Name	Drug Name	NDC	Max Allow	Max Units/Day	GAMMIS Effective Date	NOTE
1	Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s). 300 mg	Astra Zeneca	EVUSHELD 150-150MG/1.5ML Solution	00310-1061-01 00310-7442-02 00310-8895-01	\$0.00	1	12/8/2021	Report Q0220 with administration codes M0220, M0221
2	Q0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s). 600 mg	AstraZeneca	Tixagev and cilgav, 600mg	00310-1061-01 00310-7442-02 00310-8895-01	\$0.00	1	2/24/2022	Report Q0221 with administration codes M0220, M0221
3	M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring	Astra Zeneca	N/A	N/A	\$120.00	1	12/8/2021	Report M0220 with Q0220 & Q0221
4	M0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Astra Zeneca	N/A	N/A	\$200.00	1	12/8/2021	Report M0221 with Q0220 & Q0221 for home administration
5	Q0222	Bebtelovimab, 175 mg	Eli Lilly	BEBTELOVIMA	00002-7589-01	\$0.00	1	2/11/2022	Report Q0222 with administration codes M0222, M0223
6	M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	Eli Lilly	N/A	N/A	\$280.00	1	2/11/2022	Report M0222 with Q0222
7	M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Eli Lilly	N/A	N/A	\$440.00	1	2/11/2022	Report M0223 with Q0222
8	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-00	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-01	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-00	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
	Q0240	Casirivimab and Imdevimab, 600 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-01	\$0.00	1	7/30/2021	Report Q0240 with administration codes M0240, M0241
9	M0240	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses	Regeneron	N/A	N/A	\$360.00	1	6/8/2021	Report M0240 with Q0240
10	M0241	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses	Regeneron	N/A	N/A	\$600.00	1	7/30/2021	Report M0241 with Q0240 for home/residence administration
11	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	CASIRIVIMAB 1200MG Solution	61755-0024-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	IMDEVIMAB 1200MG Solution	61755-0025-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0035-02	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0036-08	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244

COVID-19 Monoclonal Antibodies & Administration Codes									
Revised: July 1, 2022									
Submit claim for administration fee with the appropriate Monoclonal Antibody HCPCS (See NOTE tab for additional instructions)									
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0037-05	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 1200MG/1200MG Solution	61755-0038-05	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 600-600MG/10ML Solution	61755-0039-01	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 120MG/ML;120MG/ML Solution	61755-0042-02	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
	Q0243	Casirivimab and Imdevimab, 2400 mg	Regeneron	REGEN-COV 120MG/ML;120MG/ML Solution	61755-0045-02	\$0.00	1	12/1/2020	Report Q0243 with administration codes M0243, M0244
12	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	CASIRIVIMAB 300MG/2.5ML Solution	61755-0026-01	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	IMDEVIMAB 300MG/2.5ML Solution	61755-0027-01	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	REGEN-COV 600-600MG/10ML Solution	61755-0039-01	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	REGEN-COV 120MG/ML;120MG/ML Solution	61755-0042-02	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
	Q0244	Casirivimab and Imdevimab, 1200 mg	Regeneron	REGEN-COV 120MG/ML;120MG/ML Solution	61755-0045-02	\$0.00	1	6/3/2021	Report Q0244 with administration codes M0243, M0244
13	M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	Regeneron	N/A	N/A	\$360.00	1	12/1/2020	Report M0243 with Q0243/Q0244
14	M0244	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Regeneron	N/A	N/A	\$600.00	1	5/6/2021	Report M0244 with Q0243 as well as Q0244 for home/residence administration
15	Q0245	Bamlanivimab and Etesevimab, 2100 mg	Eli Lilly	BAMLANIVIMAB 700MG/20ML Solution	00002-7910-01	\$0.00	1	2/9/2021	Report Q0245 with administration codes M0245, M0246
	Q0245	Bamlanivimab and Etesevimab, 2100 mg	Eli Lilly	ETESEVIMAB 35MG/ML Solution	00002-7950-01	\$0.00	1	2/9/2021	Report Q0245 with administration codes M0245, M0246
16	M0245	intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	Eli Lilly	N/A	N/A	\$360.00	1	2/9/2021	Report M0245 with Q0245
17	M0246	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	Eli Lilly	N/A	N/A	\$600.00		5/6/2021	Report M0246 with Q0245 for home/residence administration
18	Q0247	Sotrovimab, 500 mg	GSK	SOTROVIMAB 500MG/8ML Solution	00173-0901-86	\$0.00	1	5/26/2021	Report Q0247 with administration codes M0247, M0248
19	M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	GSK	N/A	N/A	\$360.00		5/26/2021	Report M0247 with Q0247
20	M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency	GSK	N/A	N/A	\$600.00		5/26/2021	Report M0248 with Q0247 for home/residence administration
21	Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Genentech	ACTEMRA 20MG/ML Solution	50242-0135-01	\$6.57	800	6/24/2021	Report Q0249 with administration codes M0249, M0250
	Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Genentech	ACTEMRA 200MG/10ML Solution	50242-0136-01	\$6.57	800	6/24/2021	Report Q0249 with administration codes M0249, M0250
	Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg	Genentech	ACTEMRA 400MG/20ML Solution	50242-0137-01	\$6.57	800	6/24/2021	Report Q0249 with administration codes M0249, M0250
22	M0249	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose	Genentech	N/A	N/A	\$360.00	1	6/24/2021	Report M0249 with Q0294 - 1st dose

COVID-19 Monoclonal Antibodies & Administration Codes									
Revised: July 1, 2022									
Submit claim for administration fee with the appropriate Monoclonal Antibody HCPCS (See NOTE tab for additional instructions)									
23	M0250	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose	Genentech	N/A	N/A	\$360.00	1	6/24/2021	Report M0250 with Q0294 - 2nd dose